Why is the biotechnology sector outperforming the market?

biotech sector
From Sweta Jaiswal, FRM: The biotech industry has kept its promise for solid returns so far. The rally in some major biotechnology indexes reflects the same. In this context, the NASDAQ Biotechnology Index has returned 17.6% year to date. Following the trend, S&P Biotechnology Select Industry Index has returned around 29%.
NYSE:XBI April 12, 2019 2:10pm

Biotech ETF sees Big Inflow

biotech stock
From ETF Channel Staff: Investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
NYSE:XBI February 27, 2019 3:49pm

Biotech experiences a major breakout, but technician makes warning

Biotechnology Sector
From Annie Pei: Biotech's looking like a healthy bet these days.
NYSE:XBI January 14, 2019 12:18pm

Impressive Breakout From Biotechs Taking Place (XBI)

From Chris Kimble: The chart below looks at Bio-Tech ETF (XBI) over the past three years.
NYSE:XBI June 21, 2018 6:24am

Time For Biotech To Cool Off Again? (XBI)

From Dana Lyons: A popular biotech ETF is testing potentially formidable resistance on its chart.
NYSE:XBI June 13, 2018 6:09am

These Sector ETFs Are Crushing The S&P 500 (XBI)

From Zacks: The S&P 500's bull market has just turned nine. On this very day, nine years ago, stocks bottomed out only to log an amazing recovery from the deepest recession since the Great Depression.
NYSE:XBI March 11, 2018 7:31am

These ETFs Are Crushing The S&P 500 This Year (XBI)

From Contrarian Outlook: If you're like most folks, you probably think it's tough for any fund to beat the S&P 500, especially in a year when the index jumped some 15%.
NYSE:XBI October 31, 2017 7:40am

Examining The SPDR S&P Biotech ETF (XBI) Bullish Breakout

From Chris Kimble: Biotech used to be an upside leader over the broad market coming off the 2009 lows. Biotech then officially gave up its leadership back in 2015, where it peaked and started underperforming the broad market.
NYSE:XBI June 22, 2017 6:37am

Here Are The Best Performing ETFs Of 2017 Thus Far

From Moby Waller: A huge amount of money goes into passive stock market tracking these days, through the S&P 500 Index (SPY) and other major U.S. indexes (DIA) (QQQ) (IWM). This strategy has done well in general in recent years and has gained popularity, particularly in retirement-type accounts.
NYSE:XBI March 17, 2017 6:21am

This New Piece Of Legislation Could Be A Huge Boon For Pharma Companies

From Sound Dollar Campaign: During the presidential campaign, the high price of prescription drugs became a blistering issue. At the same time, the Mylan/EpiPen scandal broke.
NYSE:XBI January 6, 2017 6:33am

Biotech Stocks Plunge As Trump Vows To Lower Drug Prices

president trump photo
The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) was on the decline this morning, after Donald Trump's TIME Person of the Year profile revealed that the president-elect likely won't be the bullish force for drug companies many thought he'd be.
NASDAQ:IBB December 7, 2016 9:18am

Biotech ETFs Have Room to Run, with Several Catalysts Ahead

Biotech pillsThe iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) has recovered nicely from its yearly lows, and there's reason to believe that more gains are on the horizon as well.
NASDAQ:IBB September 30, 2016 10:22am

This Biotech ETF is Breaking Out to the Upside

From Gary Savage: Today's chart of the day focuses on a well-known biotech ETF, the SPDR S&P Biotech ETF (NYSE:XBI), which is threatening to break out even further to the upside.
NASDAQ:IBB September 20, 2016 9:23am

Can the Biotech Sector Turn it Around Before Year-End?

From Zacks Research: The biotech sector has had a rough start to the year with the NASDAQ Biotechnology Index declining approximately 16% year-to-date. Sector-specific issues like increasing political and media focus on high price tags for new drugs and the changing competitive scenario have been weighing on biotech stocks over the last few quarters.
NASDAQ:IBB September 2, 2016 7:39am

Get Free Updates

Join over 50,000 investors who get the latest news from ETFDailyNews.com!

Most Popular


From Our Partners


Explore More from ETFDailyNews.com

Free Daily Newsletter

Get daily ETF insights from our market experts. Never miss another important market development again!

ETFDailyNews.com respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories